Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Purple Innovation, Inc.PRPL · Entity 7764 | Chief Marketing Officer | June 20, 2024 | June 21, 2024 |
| TIVITY HEALTH, INC.TVTY · Entity 125776 | Division President, Nutrition | January 06, 2020 | January 08, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Purple Innovation, Inc.
Report date June 20, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 56,069 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 56,069 · Balance 56,069 F1: Each Restricted Stock Unit represents a contingent right to receive one share of Purple Innovation, Inc. Class A Common Stock. The Restricted Stock Units vest in three equal annual installments; one-third on March 31, 2025; one-half of the remainder on March 31, 2026; and the balance on March 31, 2027 (the "Vesting Period"). Fractional numbers will be rounded down to the nearest whole number. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of Purple Innovation, Inc. Class A Common Stock. The Restricted Stock Units vest in three equal annual installments; one-third on March 31, 2025; one-half of the remainder on March 31, 2026; and the balance on March 31, 2027 (the "Vesting Period"). Fractional numbers will be rounded down to the nearest whole number.
TIVITY HEALTH, INC.
Report date January 06, 2020 · Filed January 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 176,827 |
Reported balance
After 2020-01-06 transaction · row 1
1 source rowRow 1 · 2020-01-06 · Tax withholding · Disposed 14,001 · Balance 176,827 F1: Reflects 14,001 shares withheld to cover the payment of taxes following the vesting of 43,762 shares that were assumed by the Issuer in connection with the Issuer's acquisition of Nutrisystem, Inc. on March 8, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects 14,001 shares withheld to cover the payment of taxes following the vesting of 43,762 shares that were assumed by the Issuer in connection with the Issuer's acquisition of Nutrisystem, Inc. on March 8, 2019.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NUTRI SYSTEM INC /DE/
Report date March 08, 2019 · Filed March 11, 2019
Section 16 reporting ended · disclosed 2019-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-03-08 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2019-03-08 · Disposition to issuer · Disposed 241,992 · Balance 0 F1: This amount includes 10,202 shares of Issuer Common Stock subject to restricted stock awards that, subject to the terms of the Issuer's Amended and Restated 2008 Long-Term Incentive Plan, as amended (the "Plan") and the applicable award agreement issued thereunder, were previously granted to the Reporting Person and, as of the Effective Time, were converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4. F2: This amount includes 21,368 shares of Issuer Common Stock subject to PRSUs that, subject to the terms of the Plan and the applicable award agreement issued thereunder, were previously granted to the Reporting Person and, as of the Effective Time, were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4. F3: As of the effective time (the "Effective Time") of the transactions contemplated by the Agreement and Plan of Merger, dated December 9, 2018, by and among the Issuer, Tivity Health, Inc. ("Tivity Health"), and Sweet Acquisition Sub Inc., a wholly owned subsidiary of Tivity Health (the "Merger Agreement"), (i) each share of the Issuer's common stock, $0.001 par value per share ("Issuer Common Stock") held by the Reporting Person was converted into the right to receive (a) $38.75 in cash and (b) 0.2141 shares of Tivity Health common stock, par value $0.001 per share ("Tivity Health Common Stock"), plus cash in lieu of a fractional share of Tivity Health Common Stock; (ii) each option to purchase Issuer Common Stock held by the Reporting Person was cancelled and converted into the right to receive, in respect of each Net Option Share (as defined in the Merger Agreement) subject to each option, an amount in cash equal to the Merger Consideration Value (as defined in the Merger Agreement); F4: Cont'd from Footnote 3: (iii) each restricted stock award held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such restricted stock awards multiplied by (b) the Equity Award Exchange Ratio (as defined in the Merger Agreement), rounded to the nearest whole number of shares of Tivity Health Common Stock; and (iv) each performance-based restricted stock unit ("PRSUs") held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such PRSUs (based on the actual or maximum performance level achievable by the Issuer as provided in the Merger Agreement) multiplied by (b) the Equity Award Exchange Ratio, rounded to the nearest whole number of shares of Tivity Health Common Stock. |
| Common StockSEC Table I · non-derivative | Direct | 41,934 |
Reported balance
After 2019-03-08 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2019-03-08 · Grant · Acquired 41,934 · Balance 41,934 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Common StockSEC Table I · non-derivative | Direct | 35,066 |
Reported balance
After 2019-03-08 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2019-03-08 · Grant · Acquired 35,066 · Balance 35,066 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Common StockSEC Table I · non-derivative | Direct | 5,554 |
Reported balance
After 2019-03-08 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2019-03-08 · Grant · Acquired 5,554 · Balance 5,554 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Common StockSEC Table I · non-derivative | Direct | 6,042 |
Reported balance
After 2019-03-08 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2019-03-08 · Grant · Acquired 6,042 · Balance 6,042 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Common StockSEC Table I · non-derivative | Direct | 12,518 |
Reported balance
After 2019-03-08 transaction · row 6
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 6 · 2019-03-08 · Grant · Acquired 12,518 · Balance 12,518 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Common StockSEC Table I · non-derivative | Direct | 20,202 |
Reported balance
After 2019-03-08 transaction · row 7
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 7 · 2019-03-08 · Grant · Acquired 20,202 · Balance 20,202 F7: These PRSUs represented the contingent right to receive shares of Issuer Common Stock subject to the Issuer's achievement of performance conditions, subject to the terms of the Plan and the applicable award agreement issued thereunder. F8: As of the Effective Time, pursuant to the terms of the Merger Agreement, such PRSUs were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4, assuming maximum performance was achieved. |
| Common StockSEC Table I · non-derivative | Direct | 19,924 |
Reported balance
After 2019-03-08 transaction · row 8
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 8 · 2019-03-08 · Grant · Acquired 19,924 · Balance 19,924 F7: These PRSUs represented the contingent right to receive shares of Issuer Common Stock subject to the Issuer's achievement of performance conditions, subject to the terms of the Plan and the applicable award agreement issued thereunder. F8: As of the Effective Time, pursuant to the terms of the Merger Agreement, such PRSUs were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4, assuming maximum performance was achieved. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $8.38 · Expires 2020-02-11 | Direct | 0 |
Reported balance
After 2019-03-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-03-08 · Disposition to issuer · Disposed 41,934 · Balance 0 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $8.52 · Expires 2020-03-21 | Direct | 0 |
Reported balance
After 2019-03-08 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-03-08 · Disposition to issuer · Disposed 35,066 · Balance 0 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $14.95 · Expires 2021-03-20 | Direct | 0 |
Reported balance
After 2019-03-08 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-03-08 · Disposition to issuer · Disposed 5,554 · Balance 0 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.98 · Expires 2022-01-02 | Direct | 0 |
Reported balance
After 2019-03-08 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-03-08 · Disposition to issuer · Disposed 6,042 · Balance 0 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $20.94 · Expires 2023-01-04 | Direct | 0 |
Reported balance
After 2019-03-08 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-03-08 · Disposition to issuer · Disposed 12,518 · Balance 0 F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. |
| Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-03-08 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2019-03-08 · Disposition to issuer · Disposed 20,202 · Balance 0 F8: As of the Effective Time, pursuant to the terms of the Merger Agreement, such PRSUs were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4, assuming maximum performance was achieved. F7: These PRSUs represented the contingent right to receive shares of Issuer Common Stock subject to the Issuer's achievement of performance conditions, subject to the terms of the Plan and the applicable award agreement issued thereunder. F3: As of the effective time (the "Effective Time") of the transactions contemplated by the Agreement and Plan of Merger, dated December 9, 2018, by and among the Issuer, Tivity Health, Inc. ("Tivity Health"), and Sweet Acquisition Sub Inc., a wholly owned subsidiary of Tivity Health (the "Merger Agreement"), (i) each share of the Issuer's common stock, $0.001 par value per share ("Issuer Common Stock") held by the Reporting Person was converted into the right to receive (a) $38.75 in cash and (b) 0.2141 shares of Tivity Health common stock, par value $0.001 per share ("Tivity Health Common Stock"), plus cash in lieu of a fractional share of Tivity Health Common Stock; (ii) each option to purchase Issuer Common Stock held by the Reporting Person was cancelled and converted into the right to receive, in respect of each Net Option Share (as defined in the Merger Agreement) subject to each option, an amount in cash equal to the Merger Consideration Value (as defined in the Merger Agreement); F4: Cont'd from Footnote 3: (iii) each restricted stock award held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such restricted stock awards multiplied by (b) the Equity Award Exchange Ratio (as defined in the Merger Agreement), rounded to the nearest whole number of shares of Tivity Health Common Stock; and (iv) each performance-based restricted stock unit ("PRSUs") held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such PRSUs (based on the actual or maximum performance level achievable by the Issuer as provided in the Merger Agreement) multiplied by (b) the Equity Award Exchange Ratio, rounded to the nearest whole number of shares of Tivity Health Common Stock. |
| Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-03-08 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2019-03-08 · Disposition to issuer · Disposed 19,924 · Balance 0 F8: As of the Effective Time, pursuant to the terms of the Merger Agreement, such PRSUs were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4, assuming maximum performance was achieved. F7: These PRSUs represented the contingent right to receive shares of Issuer Common Stock subject to the Issuer's achievement of performance conditions, subject to the terms of the Plan and the applicable award agreement issued thereunder. F3: As of the effective time (the "Effective Time") of the transactions contemplated by the Agreement and Plan of Merger, dated December 9, 2018, by and among the Issuer, Tivity Health, Inc. ("Tivity Health"), and Sweet Acquisition Sub Inc., a wholly owned subsidiary of Tivity Health (the "Merger Agreement"), (i) each share of the Issuer's common stock, $0.001 par value per share ("Issuer Common Stock") held by the Reporting Person was converted into the right to receive (a) $38.75 in cash and (b) 0.2141 shares of Tivity Health common stock, par value $0.001 per share ("Tivity Health Common Stock"), plus cash in lieu of a fractional share of Tivity Health Common Stock; (ii) each option to purchase Issuer Common Stock held by the Reporting Person was cancelled and converted into the right to receive, in respect of each Net Option Share (as defined in the Merger Agreement) subject to each option, an amount in cash equal to the Merger Consideration Value (as defined in the Merger Agreement); F4: Cont'd from Footnote 3: (iii) each restricted stock award held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such restricted stock awards multiplied by (b) the Equity Award Exchange Ratio (as defined in the Merger Agreement), rounded to the nearest whole number of shares of Tivity Health Common Stock; and (iv) each performance-based restricted stock unit ("PRSUs") held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such PRSUs (based on the actual or maximum performance level achievable by the Issuer as provided in the Merger Agreement) multiplied by (b) the Equity Award Exchange Ratio, rounded to the nearest whole number of shares of Tivity Health Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: This amount includes 10,202 shares of Issuer Common Stock subject to restricted stock awards that, subject to the terms of the Issuer's Amended and Restated 2008 Long-Term Incentive Plan, as amended (the "Plan") and the applicable award agreement issued thereunder, were previously granted to the Reporting Person and, as of the Effective Time, were converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4.
F2: This amount includes 21,368 shares of Issuer Common Stock subject to PRSUs that, subject to the terms of the Plan and the applicable award agreement issued thereunder, were previously granted to the Reporting Person and, as of the Effective Time, were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4.
F3: As of the effective time (the "Effective Time") of the transactions contemplated by the Agreement and Plan of Merger, dated December 9, 2018, by and among the Issuer, Tivity Health, Inc. ("Tivity Health"), and Sweet Acquisition Sub Inc., a wholly owned subsidiary of Tivity Health (the "Merger Agreement"), (i) each share of the Issuer's common stock, $0.001 par value per share ("Issuer Common Stock") held by the Reporting Person was converted into the right to receive (a) $38.75 in cash and (b) 0.2141 shares of Tivity Health common stock, par value $0.001 per share ("Tivity Health Common Stock"), plus cash in lieu of a fractional share of Tivity Health Common Stock; (ii) each option to purchase Issuer Common Stock held by the Reporting Person was cancelled and converted into the right to receive, in respect of each Net Option Share (as defined in the Merger Agreement) subject to each option, an amount in cash equal to the Merger Consideration Value (as defined in the Merger Agreement);
F4: Cont'd from Footnote 3: (iii) each restricted stock award held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such restricted stock awards multiplied by (b) the Equity Award Exchange Ratio (as defined in the Merger Agreement), rounded to the nearest whole number of shares of Tivity Health Common Stock; and (iv) each performance-based restricted stock unit ("PRSUs") held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such PRSUs (based on the actual or maximum performance level achievable by the Issuer as provided in the Merger Agreement) multiplied by (b) the Equity Award Exchange Ratio, rounded to the nearest whole number of shares of Tivity Health Common Stock.
F5: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder.
F6: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value.
F7: These PRSUs represented the contingent right to receive shares of Issuer Common Stock subject to the Issuer's achievement of performance conditions, subject to the terms of the Plan and the applicable award agreement issued thereunder.
F8: As of the Effective Time, pursuant to the terms of the Merger Agreement, such PRSUs were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4, assuming maximum performance was achieved.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2024 Filed Jun 21, 2024 16:00 UTC | Purple Innovation, Inc. PRPL · Entity 7764 | GrantRestricted Stock Units · Derivative | 56,069 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-054746 · ownership.xml · derivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,069 Underlying: Class A Common Stock · 56,069 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Purple Innovation, Inc. Class A Common Stock. The Restricted Stock Units vest in three equal annual installments; one-third on March 31, 2025; one-half of the remainder on March 31, 2026; and the balance on March 31, 2027 (the "Vesting Period"). Fractional numbers will be rounded down to the nearest whole number. F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of Purple Innovation, Inc. Class A Common Stock. The Restricted Stock Units vest in three equal annual installments; one-third on March 31, 2025; one-half of the remainder on March 31, 2026; and the balance on March 31, 2027 (the "Vesting Period"). Fractional numbers will be rounded down to the nearest whole number. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of Purple Innovation, Inc. Class A Common Stock. The Restricted Stock Units vest in three equal annual installments; one-third on March 31, 2025; one-half of the remainder on March 31, 2026; and the balance on March 31, 2027 (the "Vesting Period"). Fractional numbers will be rounded down to the nearest whole number. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 16:01 UTC | Purple Innovation, Inc. PRPL · Entity 7764 | Exercise / conversionRestricted Stock Units · Derivative | 11,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-024004 · ownership.xml · derivative · entry 3 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,290 Underlying: Class A Common Stock · 11,644 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Purple Innovation, Inc. Class A Common Stock. The Restricted Stock Units vest in three equal annual installments; one-third on March 15, 2024; one-half of the remainder on March 15, 2025; and the balance on March 15, 2026 (the "Vesting Period"). Fractional numbers will be rounded down to the nearest whole number. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of Purple Innovation, Inc. Class A Common Stock. The Restricted Stock Units vest in three equal annual installments; one-third on March 15, 2024; one-half of the remainder on March 15, 2025; and the balance on March 15, 2026 (the "Vesting Period"). Fractional numbers will be rounded down to the nearest whole number. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of Purple Innovation, Inc. Class A Common Stock. The Restricted Stock Units vest in three equal annual installments; one-third on March 15, 2024; one-half of the remainder on March 15, 2025; and the balance on March 15, 2026 (the "Vesting Period"). Fractional numbers will be rounded down to the nearest whole number. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 16:01 UTC | Purple Innovation, Inc. PRPL · Entity 7764 | Tax withholdingClass A Common Stock | 4,815 | $1.56 | $7,511.40 |
DisclosureSEC source: 0001213900-24-024004 · ownership.xml · nonDerivative · entry 2 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,829 Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 16:01 UTC | Purple Innovation, Inc. PRPL · Entity 7764 | Exercise / conversionClass A Common Stock | 11,644 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-024004 · ownership.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units convert into Class A Common Stock on a one-for-one basis. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 16:00 UTC | Purple Innovation, Inc. PRPL · Entity 7764 | GrantPerformance Stock Units · Derivative | 64,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-050946 · ownership.xml · derivative · entry 2 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,878 Underlying: Class A Common Stock · 64,878 shares Expires not disclosed F2 · derivative.exercise_price: Each Performance Stock Unit represents a contingent right to receive up to one share of Purple Innovation, Inc. Class A Common Stock after March 15, 2025. Between 0% and 100% of the Performance Stock Units will vest upon Purple Innovation, Inc.'s Class A Common Stock achieving specified target price per share levels on March 15, 2026. F2 · derivative.exercise_date: Each Performance Stock Unit represents a contingent right to receive up to one share of Purple Innovation, Inc. Class A Common Stock after March 15, 2025. Between 0% and 100% of the Performance Stock Units will vest upon Purple Innovation, Inc.'s Class A Common Stock achieving specified target price per share levels on March 15, 2026. F2 · derivative.expiration_date: Each Performance Stock Unit represents a contingent right to receive up to one share of Purple Innovation, Inc. Class A Common Stock after March 15, 2025. Between 0% and 100% of the Performance Stock Units will vest upon Purple Innovation, Inc.'s Class A Common Stock achieving specified target price per share levels on March 15, 2026. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 16:00 UTC | Purple Innovation, Inc. PRPL · Entity 7764 | GrantRestricted Stock Units · Derivative | 34,934 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-050946 · ownership.xml · derivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,934 Underlying: Class A Common Stock · 34,934 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Purple Innovation, Inc. Class A Common Stock. The Restricted Stock Units vest in three equal annual installments; one-third on March 15, 2024; one-half of the remainder on March 15, 2025; and the balance on March 15, 2026 (the "Vesting Period"). Fractional numbers will be rounded down to the nearest whole number. F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of Purple Innovation, Inc. Class A Common Stock. The Restricted Stock Units vest in three equal annual installments; one-third on March 15, 2024; one-half of the remainder on March 15, 2025; and the balance on March 15, 2026 (the "Vesting Period"). Fractional numbers will be rounded down to the nearest whole number. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of Purple Innovation, Inc. Class A Common Stock. The Restricted Stock Units vest in three equal annual installments; one-third on March 15, 2024; one-half of the remainder on March 15, 2025; and the balance on March 15, 2026 (the "Vesting Period"). Fractional numbers will be rounded down to the nearest whole number. Read SEC document |
| November 11, 2022 Filed Nov 29, 2022 16:16 UTC | Purple Innovation, Inc. PRPL · Entity 7764 | GrantPerformance Stock Units · Derivative | 75,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-075886 · ownership.xml · derivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,757 Underlying: Class A Common Stock · 75,757 shares Expires not disclosed F1 · derivative.exercise_price: Each Performance Stock Unit represents a contingent right to receive up to one share of Purple Innovation, Inc. Class A Common Stock after November 11, 2025. Between 0% and 100% of the Performance Stock Units will vest upon Purple Innovation, Inc.'s Class A Common Stock achieving specified target price per share levels on November 11, 2025. F1 · derivative.exercise_date: Each Performance Stock Unit represents a contingent right to receive up to one share of Purple Innovation, Inc. Class A Common Stock after November 11, 2025. Between 0% and 100% of the Performance Stock Units will vest upon Purple Innovation, Inc.'s Class A Common Stock achieving specified target price per share levels on November 11, 2025. F1 · derivative.expiration_date: Each Performance Stock Unit represents a contingent right to receive up to one share of Purple Innovation, Inc. Class A Common Stock after November 11, 2025. Between 0% and 100% of the Performance Stock Units will vest upon Purple Innovation, Inc.'s Class A Common Stock achieving specified target price per share levels on November 11, 2025. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 14:34 UTC | TIVITY HEALTH, INC. TVTY · Entity 125776 | Tax withholdingCommon Stock | 14,001 | $21.22 | $297,101.22 |
DisclosureSEC source: 0001567619-20-000750 · doc1.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Division President, Nutrition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,827 F1 · shares: Reflects 14,001 shares withheld to cover the payment of taxes following the vesting of 43,762 shares that were assumed by the Issuer in connection with the Issuer's acquisition of Nutrisystem, Inc. on March 8, 2019. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 17:31 UTC | TIVITY HEALTH, INC. TVTY · Entity 125776 | Tax withholdingCommon Stock | 2,051 | $20.32 | $41,676.32 |
DisclosureSEC source: 0001567619-20-000621 · doc1.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Division President, Nutrition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,828 F1 · shares: Reflects 2,051 shares withheld to cover the payment of taxes following the vesting of 7,293 shares that were assumed by the Issuer in connection with the Issuer's acquisition of Nutrisystem, Inc. on March 8, 2019. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 15:40 UTC | TIVITY HEALTH, INC. TVTY · Entity 125776 | Tax withholdingCommon Stock | 2,289 | $20.68 | $47,336.52 |
DisclosureSEC source: 0001567619-20-000289 · doc1.xml · nonDerivative · entry 2 Krausz Keira · CIK 0001569574 · Division President, Nutrition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,879 F2 · shares: Reflects 2,289 shares withheld to cover the payment of taxes following the vesting of 6,800 shares that were assumed by the Issuer in connection with the Issuer's acquisition of Nutrisystem, Inc. on March 8, 2019. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 15:40 UTC | TIVITY HEALTH, INC. TVTY · Entity 125776 | Tax withholdingCommon Stock | 17,990 | $20.35 | $366,006.55 |
DisclosureSEC source: 0001567619-20-000289 · doc1.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Division President, Nutrition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,168 F1 · shares: Reflects 17,990 shares withheld to cover the payment of taxes following the vesting of 41,374 shares that were assumed by the Issuer in connection with the Issuer's acquisition of Nutrisystem, Inc. on March 8, 2019. Read SEC document |
| April 11, 2019 Filed May 7, 2019 18:22 UTC | TIVITY HEALTH, INC. TVTY · Entity 125776 | GrantCommon Stock | 12,893 | $20.36 | $262,501.48 |
DisclosureSEC source: 0001567619-19-010068 · doc1.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Division President, Nutrition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,158 F1 · shares: Reflects the annual grant of restricted stock units. Restricted stock units vest 33% on 4/11/2020, 33% on 4/11/2021, and 34% on 4/11/2022. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 14:55 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Disposition to issuerPerformance-Based Restricted Stock Units · Derivative | 19,924 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-018372 · doc4.xml · derivative · entry 15 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,924 shares Expires not disclosed F8 · derivative.exercise_price: As of the Effective Time, pursuant to the terms of the Merger Agreement, such PRSUs were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4, assuming maximum performance was achieved. F7 · kind: These PRSUs represented the contingent right to receive shares of Issuer Common Stock subject to the Issuer's achievement of performance conditions, subject to the terms of the Plan and the applicable award agreement issued thereunder. F8 · price: As of the Effective Time, pursuant to the terms of the Merger Agreement, such PRSUs were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4, assuming maximum performance was achieved. F3 · derivative.exercise_date: As of the effective time (the "Effective Time") of the transactions contemplated by the Agreement and Plan of Merger, dated December 9, 2018, by and among the Issuer, Tivity Health, Inc. ("Tivity Health"), and Sweet Acquisition Sub Inc., a wholly owned subsidiary of Tivity Health (the "Merger Agreement"), (i) each share of the Issuer's common stock, $0.001 par value per share ("Issuer Common Stock") held by the Reporting Person was converted into the right to receive (a) $38.75 in cash and (b) 0.2141 shares of Tivity Health common stock, par value $0.001 per share ("Tivity Health Common Stock"), plus cash in lieu of a fractional share of Tivity Health Common Stock; (ii) each option to purchase Issuer Common Stock held by the Reporting Person was cancelled and converted into the right to receive, in respect of each Net Option Share (as defined in the Merger Agreement) subject to each option, an amount in cash equal to the Merger Consideration Value (as defined in the Merger Agreement); F4 · derivative.exercise_date: Cont'd from Footnote 3: (iii) each restricted stock award held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such restricted stock awards multiplied by (b) the Equity Award Exchange Ratio (as defined in the Merger Agreement), rounded to the nearest whole number of shares of Tivity Health Common Stock; and (iv) each performance-based restricted stock unit ("PRSUs") held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such PRSUs (based on the actual or maximum performance level achievable by the Issuer as provided in the Merger Agreement) multiplied by (b) the Equity Award Exchange Ratio, rounded to the nearest whole number of shares of Tivity Health Common Stock. F3 · derivative.expiration_date: As of the effective time (the "Effective Time") of the transactions contemplated by the Agreement and Plan of Merger, dated December 9, 2018, by and among the Issuer, Tivity Health, Inc. ("Tivity Health"), and Sweet Acquisition Sub Inc., a wholly owned subsidiary of Tivity Health (the "Merger Agreement"), (i) each share of the Issuer's common stock, $0.001 par value per share ("Issuer Common Stock") held by the Reporting Person was converted into the right to receive (a) $38.75 in cash and (b) 0.2141 shares of Tivity Health common stock, par value $0.001 per share ("Tivity Health Common Stock"), plus cash in lieu of a fractional share of Tivity Health Common Stock; (ii) each option to purchase Issuer Common Stock held by the Reporting Person was cancelled and converted into the right to receive, in respect of each Net Option Share (as defined in the Merger Agreement) subject to each option, an amount in cash equal to the Merger Consideration Value (as defined in the Merger Agreement); F4 · derivative.expiration_date: Cont'd from Footnote 3: (iii) each restricted stock award held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such restricted stock awards multiplied by (b) the Equity Award Exchange Ratio (as defined in the Merger Agreement), rounded to the nearest whole number of shares of Tivity Health Common Stock; and (iv) each performance-based restricted stock unit ("PRSUs") held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such PRSUs (based on the actual or maximum performance level achievable by the Issuer as provided in the Merger Agreement) multiplied by (b) the Equity Award Exchange Ratio, rounded to the nearest whole number of shares of Tivity Health Common Stock. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 14:55 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Disposition to issuerPerformance-Based Restricted Stock Units · Derivative | 20,202 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-018372 · doc4.xml · derivative · entry 14 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,202 shares Expires not disclosed F8 · derivative.exercise_price: As of the Effective Time, pursuant to the terms of the Merger Agreement, such PRSUs were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4, assuming maximum performance was achieved. F7 · kind: These PRSUs represented the contingent right to receive shares of Issuer Common Stock subject to the Issuer's achievement of performance conditions, subject to the terms of the Plan and the applicable award agreement issued thereunder. F8 · price: As of the Effective Time, pursuant to the terms of the Merger Agreement, such PRSUs were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4, assuming maximum performance was achieved. F3 · derivative.exercise_date: As of the effective time (the "Effective Time") of the transactions contemplated by the Agreement and Plan of Merger, dated December 9, 2018, by and among the Issuer, Tivity Health, Inc. ("Tivity Health"), and Sweet Acquisition Sub Inc., a wholly owned subsidiary of Tivity Health (the "Merger Agreement"), (i) each share of the Issuer's common stock, $0.001 par value per share ("Issuer Common Stock") held by the Reporting Person was converted into the right to receive (a) $38.75 in cash and (b) 0.2141 shares of Tivity Health common stock, par value $0.001 per share ("Tivity Health Common Stock"), plus cash in lieu of a fractional share of Tivity Health Common Stock; (ii) each option to purchase Issuer Common Stock held by the Reporting Person was cancelled and converted into the right to receive, in respect of each Net Option Share (as defined in the Merger Agreement) subject to each option, an amount in cash equal to the Merger Consideration Value (as defined in the Merger Agreement); F4 · derivative.exercise_date: Cont'd from Footnote 3: (iii) each restricted stock award held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such restricted stock awards multiplied by (b) the Equity Award Exchange Ratio (as defined in the Merger Agreement), rounded to the nearest whole number of shares of Tivity Health Common Stock; and (iv) each performance-based restricted stock unit ("PRSUs") held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such PRSUs (based on the actual or maximum performance level achievable by the Issuer as provided in the Merger Agreement) multiplied by (b) the Equity Award Exchange Ratio, rounded to the nearest whole number of shares of Tivity Health Common Stock. F3 · derivative.expiration_date: As of the effective time (the "Effective Time") of the transactions contemplated by the Agreement and Plan of Merger, dated December 9, 2018, by and among the Issuer, Tivity Health, Inc. ("Tivity Health"), and Sweet Acquisition Sub Inc., a wholly owned subsidiary of Tivity Health (the "Merger Agreement"), (i) each share of the Issuer's common stock, $0.001 par value per share ("Issuer Common Stock") held by the Reporting Person was converted into the right to receive (a) $38.75 in cash and (b) 0.2141 shares of Tivity Health common stock, par value $0.001 per share ("Tivity Health Common Stock"), plus cash in lieu of a fractional share of Tivity Health Common Stock; (ii) each option to purchase Issuer Common Stock held by the Reporting Person was cancelled and converted into the right to receive, in respect of each Net Option Share (as defined in the Merger Agreement) subject to each option, an amount in cash equal to the Merger Consideration Value (as defined in the Merger Agreement); F4 · derivative.expiration_date: Cont'd from Footnote 3: (iii) each restricted stock award held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such restricted stock awards multiplied by (b) the Equity Award Exchange Ratio (as defined in the Merger Agreement), rounded to the nearest whole number of shares of Tivity Health Common Stock; and (iv) each performance-based restricted stock unit ("PRSUs") held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such PRSUs (based on the actual or maximum performance level achievable by the Issuer as provided in the Merger Agreement) multiplied by (b) the Equity Award Exchange Ratio, rounded to the nearest whole number of shares of Tivity Health Common Stock. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 14:55 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Disposition to issuerOption to Purchase Common Stock · Derivative | 12,518 | Not disclosed Strike: $20.94 | Not disclosed |
DisclosureSEC source: 0001209191-19-018372 · doc4.xml · derivative · entry 13 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,518 shares Expires 2023-01-04 F5 · kind: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6 · price: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 14:55 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Disposition to issuerOption to Purchase Common Stock · Derivative | 6,042 | Not disclosed Strike: $18.98 | Not disclosed |
DisclosureSEC source: 0001209191-19-018372 · doc4.xml · derivative · entry 12 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,042 shares Expires 2022-01-02 F5 · kind: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6 · price: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 14:55 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Disposition to issuerOption to Purchase Common Stock · Derivative | 5,554 | Not disclosed Strike: $14.95 | Not disclosed |
DisclosureSEC source: 0001209191-19-018372 · doc4.xml · derivative · entry 11 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,554 shares Expires 2021-03-20 F5 · kind: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6 · price: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 14:55 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Disposition to issuerOption to Purchase Common Stock · Derivative | 35,066 | Not disclosed Strike: $8.52 | Not disclosed |
DisclosureSEC source: 0001209191-19-018372 · doc4.xml · derivative · entry 10 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,066 shares Expires 2020-03-21 F5 · kind: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6 · price: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 14:55 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Disposition to issuerOption to Purchase Common Stock · Derivative | 41,934 | Not disclosed Strike: $8.38 | Not disclosed |
DisclosureSEC source: 0001209191-19-018372 · doc4.xml · derivative · entry 9 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,934 shares Expires 2020-02-11 F5 · kind: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6 · price: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 14:55 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | GrantCommon Stock | 19,924 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-018372 · doc4.xml · nonDerivative · entry 8 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,924 F7 · price: These PRSUs represented the contingent right to receive shares of Issuer Common Stock subject to the Issuer's achievement of performance conditions, subject to the terms of the Plan and the applicable award agreement issued thereunder. F8 · price: As of the Effective Time, pursuant to the terms of the Merger Agreement, such PRSUs were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4, assuming maximum performance was achieved. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 14:55 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | GrantCommon Stock | 20,202 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-018372 · doc4.xml · nonDerivative · entry 7 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,202 F7 · price: These PRSUs represented the contingent right to receive shares of Issuer Common Stock subject to the Issuer's achievement of performance conditions, subject to the terms of the Plan and the applicable award agreement issued thereunder. F8 · price: As of the Effective Time, pursuant to the terms of the Merger Agreement, such PRSUs were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4, assuming maximum performance was achieved. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 14:55 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | GrantCommon Stock | 12,518 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-018372 · doc4.xml · nonDerivative · entry 6 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,518 F5 · price: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6 · price: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 14:55 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | GrantCommon Stock | 6,042 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-018372 · doc4.xml · nonDerivative · entry 5 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,042 F5 · price: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6 · price: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 14:55 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | GrantCommon Stock | 5,554 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-018372 · doc4.xml · nonDerivative · entry 4 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,554 F5 · price: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6 · price: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 14:55 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | GrantCommon Stock | 35,066 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-018372 · doc4.xml · nonDerivative · entry 3 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,066 F5 · price: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6 · price: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 14:55 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | GrantCommon Stock | 41,934 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-018372 · doc4.xml · nonDerivative · entry 2 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,934 F5 · price: At grant, this stock option represented the right to purchase shares of Issuer Common Stock subject to the terms of the Plan and the applicable award agreement issued thereunder. F6 · price: As of the Effective Time, pursuant to the terms of the Merger Agreement, this stock option was cancelled and converted into the right to receive, in respect of each Net Option Share subject to this stock option, an amount in cash equal to the Merger Consideration Value. Read SEC document |
| March 08, 2019 Filed Mar 11, 2019 14:55 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Disposition to issuerCommon Stock | 241,992 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-018372 · doc4.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: This amount includes 10,202 shares of Issuer Common Stock subject to restricted stock awards that, subject to the terms of the Issuer's Amended and Restated 2008 Long-Term Incentive Plan, as amended (the "Plan") and the applicable award agreement issued thereunder, were previously granted to the Reporting Person and, as of the Effective Time, were converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4. F2 · shares: This amount includes 21,368 shares of Issuer Common Stock subject to PRSUs that, subject to the terms of the Plan and the applicable award agreement issued thereunder, were previously granted to the Reporting Person and, as of the Effective Time, were converted into the right to receive an amount of time-vesting restricted Tivity Health Common Stock as described in Footnotes 3 and 4. F3 · price: As of the effective time (the "Effective Time") of the transactions contemplated by the Agreement and Plan of Merger, dated December 9, 2018, by and among the Issuer, Tivity Health, Inc. ("Tivity Health"), and Sweet Acquisition Sub Inc., a wholly owned subsidiary of Tivity Health (the "Merger Agreement"), (i) each share of the Issuer's common stock, $0.001 par value per share ("Issuer Common Stock") held by the Reporting Person was converted into the right to receive (a) $38.75 in cash and (b) 0.2141 shares of Tivity Health common stock, par value $0.001 per share ("Tivity Health Common Stock"), plus cash in lieu of a fractional share of Tivity Health Common Stock; (ii) each option to purchase Issuer Common Stock held by the Reporting Person was cancelled and converted into the right to receive, in respect of each Net Option Share (as defined in the Merger Agreement) subject to each option, an amount in cash equal to the Merger Consideration Value (as defined in the Merger Agreement); F4 · price: Cont'd from Footnote 3: (iii) each restricted stock award held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such restricted stock awards multiplied by (b) the Equity Award Exchange Ratio (as defined in the Merger Agreement), rounded to the nearest whole number of shares of Tivity Health Common Stock; and (iv) each performance-based restricted stock unit ("PRSUs") held by the Reporting Person was converted into the right to receive an amount in time-vesting restricted Tivity Health Common Stock equal to the product of (a) the number of shares of Issuer Common Stock subject to such PRSUs (based on the actual or maximum performance level achievable by the Issuer as provided in the Merger Agreement) multiplied by (b) the Equity Award Exchange Ratio, rounded to the nearest whole number of shares of Tivity Health Common Stock. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 19:07 UTC | TIVITY HEALTH, INC. TVTY · Entity 125776 | GrantCommon Stock | 185,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-006748 · doc1.xml · nonDerivative · entry 2 Krausz Keira · CIK 0001569574 · Division President, Nutrition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,673 F2 · shares: Reflects (A) the following awards that were assumed by the Issuer in connection with the Merger: (i) an award of 20,894 shares of restricted stock, of which 6,800 shares vest in full on January 2, 2020, 7,293 shares vest in full on January 3, 2020, and 6,801 shares vest in full on January 2, 2021; (ii) an award of 41,374 restricted stock units that vest in full on December 31, 2019; (iii) an award of 43,762 restricted stock units that vest in full on December 31, 2019; and (iv) an award of 40,804 restricted stock units that vest in full on December 31, 2020; and (B) an award of 38,620 restricted stock units of which 33% vests on March 8, 2020, 33% vests on March 8, 2021, and 34% vests on March 8, 2022, that was issued under the Issuer's Amended and Restated 2014 Stock Incentive Plan. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 19:07 UTC | TIVITY HEALTH, INC. TVTY · Entity 125776 | GrantCommon Stock | 43,219 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-006748 · doc1.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Division President, Nutrition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,219 F1 · price: Received in exchange for 201,866 shares of common stock of Nutrisystem, Inc. ("Nutrisystem") in connection with the merger (the "Merger") of Nutrisystem with and into Sweet Acquisition, Inc. ("Merger Sub"), pursuant to that certain Agreement and Plan of Merger, dated December 9, 2018, by and between the Issuer, Merger Sub and Nutrisystem. On March 7, 2019, the last date on which Nutrisystem's common stock was publicly traded, the closing price of Nutrisystem's common stock was $42.89 per share, and on March 8, 2019, the date of the effective time of the Merger, the closing price of the Issuer's common stock was $19.42 per share. Read SEC document |
| March 08, 2019 Filed Apr 12, 2019 14:26 UTC Amendment | TIVITY HEALTH, INC. TVTY · Entity 125776 | GrantCommon Stock | 14,811 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-008742 · doc1.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Division President, Nutrition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,265 F2 · shares: Reflects a decrease of 28,408 shares previously reported as owned by the Reporting Person on the original Form 4 filed on March 12, 2019. F1 · price: Received in exchange for 69,182 shares of common stock of Nutrisystem, Inc. ("Nutrisystem") in connection with the merger (the "Merger") of Nutrisystem with and into Sweet Acquisition, Inc. ("Merger Sub"), pursuant to that certain Agreement and Plan of Merger, dated December 9, 2018, by and between the Issuer, Merger Sub and Nutrisystem. On March 7, 2019, the last day on which Nutrisystem's common stock was publicly traded, the closing price of Nutrisystem common stock was $42.89 per share, and on March 8, 2019, the date of the effective time of the Merger, the closing price of the Issuer's common stock was $19.42 per share. F2 · balance_after: Reflects a decrease of 28,408 shares previously reported as owned by the Reporting Person on the original Form 4 filed on March 12, 2019. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 08:02 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | GrantCommon stock | 21,368 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-010870 · doc4.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,752 F1 · security: Restricted stock units were granted upon the achievement of certain specified performance goals and will vest, subject to continued employment, on December 31, 2019. Read SEC document |
| January 04, 2019 Filed Jan 7, 2019 16:03 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Tax withholdingCommon stock | 510 | $43.98 | $22,429.80 |
DisclosureSEC source: 0001209191-19-002486 · doc4.xml · nonDerivative · entry 2 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,384 F1 · shares: Withholding of common stock to cover tax liability. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 16:03 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Tax withholdingCommon stock | 1,006 | $43.45 | $43,710.70 |
DisclosureSEC source: 0001209191-19-002486 · doc4.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,894 F1 · shares: Withholding of common stock to cover tax liability. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 16:02 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Tax withholdingCommon stock | 1,082 | $43.48 | $47,045.36 |
DisclosureSEC source: 0001209191-19-000854 · doc4.xml · nonDerivative · entry 2 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,900 F1 · shares: Withholding of common stock to cover tax liability. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 16:02 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Tax withholdingCommon stock | 9,344 | $43.88 | $410,014.72 |
DisclosureSEC source: 0001209191-19-000854 · doc4.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,982 F1 · shares: Withholding of common stock to cover tax liability. Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 16:05 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Tax withholdingCommon stock | 627 | $29.55 | $18,527.85 |
DisclosureSEC source: 0001209191-18-021239 · doc4.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,326 F1 · shares: Withholding of common stock to cover tax liability. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 16:29 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | GrantCommon stock | 21,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-012426 · doc4.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,953 F1 · security: Restricted stock units were granted upon the achievement of certain specified performance goals and will vest, subject to continued employment, on December 31, 2018. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 17:33 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Exercise / conversionCommon stock options, .001 (right to buy) · Derivative | 5,000 | $0.00 Strike: $8.52 | $0.00 |
DisclosureSEC source: 0001209191-18-003455 · doc4.xml · derivative · entry 3 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,114 Underlying: Common Shares · 5,000 shares Expires 2020-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 17:33 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | SaleCommon stock | 5,000 | $50.96 | $254,822.50 |
DisclosureSEC source: 0001209191-18-003455 · doc4.xml · nonDerivative · entry 2 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,463 F1 · kind: Sale pursuant to a 10(b)5-1 plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.70 to $51.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 17:33 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Exercise / conversionCommon stock | 5,000 | $8.52 | $42,600.00 |
DisclosureSEC source: 0001209191-18-003455 · doc4.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 17:22 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Tax withholdingCommon stock | 564 | $50.40 | $28,425.60 |
DisclosureSEC source: 0001209191-18-002509 · doc4.xml · nonDerivative · entry 2 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,463 F1 · shares: Withholding of common stock to cover tax liability. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 17:22 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Tax withholdingCommon stock | 1,143 | $52.05 | $59,493.15 |
DisclosureSEC source: 0001209191-18-002509 · doc4.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,027 F1 · shares: Withholding of common stock to cover tax liability. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 17:20 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | GrantCommon stock | 9,962 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001140 · doc4.xml · nonDerivative · entry 3 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,170 F2 · shares: Restricted shares were granted on January 2, 2018. Shares vest over three years in equal installments on January 2nd of each year. Price per share on day of grant is $52.70. F2 · price: Restricted shares were granted on January 2, 2018. Shares vest over three years in equal installments on January 2nd of each year. Price per share on day of grant is $52.70. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 17:20 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Tax withholdingCommon stock | 557 | $52.70 | $29,353.90 |
DisclosureSEC source: 0001209191-18-001140 · doc4.xml · nonDerivative · entry 2 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,208 F1 · shares: Withholding of common stock to cover tax liability. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 17:20 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Tax withholdingCommon stock | 6,200 | $52.60 | $326,120.00 |
DisclosureSEC source: 0001209191-18-001140 · doc4.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,765 F1 · shares: Withholding of common stock to cover tax liability. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:04 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Exercise / conversionCommon stock options, .001 (right to buy) · Derivative | 4,446 | $0.00 Strike: $8.52 | $0.00 |
DisclosureSEC source: 0001209191-17-065407 · doc4.xml · derivative · entry 5 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,114 Underlying: Common Shares · 4,446 shares Expires 2020-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 3,628 shares became exercisable on March 21, 2014 and 818 shares became exercisable on March 21, 2015. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:04 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Exercise / conversionCommon stock options, .001 (right to buy) · Derivative | 5,554 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0001209191-17-065407 · doc4.xml · derivative · entry 4 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,560 Underlying: Common Shares · 5,554 shares Expires 2021-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:04 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | SaleCommon stock | 10,000 | $51.20 | $511,968.00 |
DisclosureSEC source: 0001209191-17-065407 · doc4.xml · nonDerivative · entry 3 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,965 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.0500 to $51.3750, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:04 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Exercise / conversionCommon stock | 4,446 | $8.52 | $37,879.92 |
DisclosureSEC source: 0001209191-17-065407 · doc4.xml · nonDerivative · entry 2 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 16:04 UTC | NUTRI SYSTEM INC /DE/ NTRI · Entity 159276 | Exercise / conversionCommon stock | 5,554 | $14.95 | $83,032.30 |
DisclosureSEC source: 0001209191-17-065407 · doc4.xml · nonDerivative · entry 1 Krausz Keira · CIK 0001569574 · Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.